Grifols earns its first Fitch corporate rating with a BB- and stable outlook

- Fitch Rating, like S&P, affirms Grifols' BB- corporate (CFR) and assigns BB+ to senior secured debt and B+ to senior unsecured debt

- Grifols’ latest ratings highlight its continued solid market position, robust business model, cash-generation capacity, and the significant added value of the Biotest transaction

- Grifols expects its leverage ratio to fall below 3.5x in 2024

Barcelona, September 27, 2021.- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS) earned its first credit rating from Fitch Rating, which joins other agencies like S&P and Moody's in evaluating the company's issue of EUR 2,000 million in senior unsecured notes with a 7-year maturity, launched to finance the Biotest transaction.

Specifically, Fitch Rating ranked Grifols' corporate family rating (CFR) BB- with an outlook of “stable,” and assigns BB+ and B+ to senior secured debt and to senior unsecured debt, respectively.

This rating is in line with S&P’s rating, which affirmed Grifols' BB- CFR with a negative outlook and BB and B for its senior secured and senior unsecured senior debt, respectively. This credit rating is one notch above Moody’s corporate credit rating and two notches above senior secured and senior unsecured debt.

These analyses still reflect Grifols’ solid market position, robust vertically integrated business model and solid fundamentals, which will continue to generate important operating cash flows and help the company reduce its leverage.

For Alfredo Arroyo, Grifols CFO, “We are pleased with the market’s vote of confidence ahead of the Biotest transaction, which represents a unique and transformational opportunity to significantly reinforce our market position, accelerating and expanding our product portfolio, and in turn, boosting our growth and profitability. Based on our forecasts, we will achieve over EUR 7 billion in combined revenues, more than EUR 2 billion in EBITDA and a more than 30% EBITDA margin. All of this will contribute to swiftly and progressively decrease our leverage ratio below 3.5x by 2024.”

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with close to 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2020, Grifols’ economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced jobs.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com
the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.